carboplatin + paclitaxel + vadimezan

The combination of carboplatin, paclitaxel, and vadimezan (also known as ASA404 or 5,6-dimethylxanthenone-4-acetic acid) was investigated as a potential treatment for advanced non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). This combination therapy was studied in clinical trials, particularly in Phase III trials, to determine if adding the vascular disrupting agent vadimezan to the standard chemotherapy regimen of carboplatin and paclitaxel would improve survival outcomes. ## Mechanism of Action The combination works through multiple mechanisms: - **Carboplatin**: A platinum-based chemotherapy drug that forms DNA crosslinks, preventing DNA replication and causing cancer cell death. - **Paclitaxel (Taxol)**: A taxane that stabilizes microtubules, preventing their breakdown during cell division, which leads to cell cycle arrest and apoptosis. - **Vadimezan (ASA404)**: A tumor vascular disrupting agent that targets the blood vessels supplying tumors, causing vascular collapse and tumor necrosis. ## Clinical Development The ATTRACT-1 trial was a global, randomized, double-blind, placebo-controlled Phase III study conducted at more than 200 sites in 20 countries to evaluate this combination in patients with stage IIIB/IV NSCLC who had not previously received systemic therapy for metastatic disease[3]. Unfortunately, the trial was stopped for futility at interim analysis as the addition of ASA404 to carboplatin and paclitaxel failed to improve frontline efficacy in advanced NSCLC[1][3]. A similar study (SAKK 15) investigating this combination in extensive-stage small-cell lung cancer was also prematurely stopped after 17 of 56 planned patients were accrued, due to negative results with ASA404 in non-small-cell lung cancer trials[2]. ## Administration Protocol In the clinical trials, the administration sequence was important - paclitaxel was administered before carboplatin to maintain efficacy, as carboplatin can interfere with paclitaxel's cytotoxic effects if given first[8]. The typical dosing regimen was: - Paclitaxel: 200 mg/m² as a 3-hour IV infusion - Carboplatin: AUC 6.0 - ASA404 (vadimezan): 1,800 mg/m² These were administered intravenously once every 3 weeks for up to six cycles[1][3]. ## Safety Profile The combination of carboplatin, paclitaxel, and vadimezan was generally well tolerated, with adverse events comparable to those seen with carboplatin and paclitaxel alone. However, Grade 4 neutropenia (27% vs 19%) and infusion site pain (10% vs 0.5%) were reported more frequently in the ASA404 arm compared to the placebo arm[3]. In the Japanese Phase I study, the most frequently reported adverse events were injection site pain, peripheral sensory neuropathy, alopecia, neutropenia, nausea, anorexia, and arthralgia[7]. Despite the promising mechanism of action and generally acceptable safety profile, the combination did not demonstrate improved efficacy over standard carboplatin and paclitaxel therapy in clinical trials, leading to the termination of its development for lung cancer.

Other names

5,6-dimethylxanthenone-4-acetic acid